CN103364498B - 生物样本中美他卡韦及其代谢产物浓度的检测方法 - Google Patents
生物样本中美他卡韦及其代谢产物浓度的检测方法 Download PDFInfo
- Publication number
- CN103364498B CN103364498B CN201210404133.6A CN201210404133A CN103364498B CN 103364498 B CN103364498 B CN 103364498B CN 201210404133 A CN201210404133 A CN 201210404133A CN 103364498 B CN103364498 B CN 103364498B
- Authority
- CN
- China
- Prior art keywords
- sample
- pna
- ddg
- concentration
- tinidazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002207 metabolite Substances 0.000 title claims abstract description 11
- 238000001514 detection method Methods 0.000 title claims abstract description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 44
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960005053 tinidazole Drugs 0.000 claims abstract description 22
- 238000004445 quantitative analysis Methods 0.000 claims abstract description 4
- 239000000523 sample Substances 0.000 claims description 72
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 claims description 27
- 210000002700 urine Anatomy 0.000 claims description 18
- 239000006228 supernatant Substances 0.000 claims description 17
- 150000002500 ions Chemical class 0.000 claims description 8
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 claims description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 238000002203 pretreatment Methods 0.000 claims description 4
- 238000000889 atomisation Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 238000000622 liquid--liquid extraction Methods 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 230000003595 spectral effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 21
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 abstract description 14
- 238000000926 separation method Methods 0.000 abstract 1
- 238000010200 validation analysis Methods 0.000 abstract 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 20
- 210000002381 plasma Anatomy 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 238000000605 extraction Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000011159 matrix material Substances 0.000 description 15
- 238000011084 recovery Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 5
- 239000005695 Ammonium acetate Substances 0.000 description 5
- 229940043376 ammonium acetate Drugs 0.000 description 5
- 235000019257 ammonium acetate Nutrition 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- -1 Nitre azoles Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000010355 oscillation Effects 0.000 description 4
- 239000013062 quality control Sample Substances 0.000 description 4
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- YKBGVTZYEHREMT-UHFFFAOYSA-N 2-amino-9-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108700024845 Hepatitis B virus P Proteins 0.000 description 1
- 241000709715 Hepatovirus Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010813 internal standard method Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
浓度(ng/mL) | 基质效应(%) | RSD(%) |
0.2 | 89.6±8.0 | 8.9 |
10 | 94.3±6.7 | 7.1 |
1000 | 102.7±6.1 | 5.9 |
浓度(ng/mL) | 基质效应(%) | RSD(%) |
0.2 | 91.4±8.6 | 9.4 |
10 | 89.7±5.5 | 6.1 |
1000 | 104.5±5.6 | 5.4 |
浓度(ng/mL) | 基质效应(%) | RSD(%) |
0.4 | 93.7±7.9 | 8.4 |
20 | 104.2±7.2 | 6.9 |
2000 | 95.1±4.5 | 4.7 |
浓度(ng/mL) | 基质效应(%) | RSD(%) |
0.2 | 89.1±8.5 | 9.5 |
10 | 96.4±7.1 | 7.4 |
1000 | 105.2±5.9 | 5.6 |
浓度(ng/mL) | 基质效应(%) | RSD(%) |
0.2 | 100.3±8.4 | 8.4 |
10 | 95.1±5.9 | 6.2 |
1000 | 101.7±5.8 | 5.7 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210404133.6A CN103364498B (zh) | 2012-04-10 | 2012-12-24 | 生物样本中美他卡韦及其代谢产物浓度的检测方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210101312 | 2012-04-10 | ||
CN201210101312.2 | 2012-04-10 | ||
CN2012101013122 | 2012-04-10 | ||
CN201210404133.6A CN103364498B (zh) | 2012-04-10 | 2012-12-24 | 生物样本中美他卡韦及其代谢产物浓度的检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103364498A CN103364498A (zh) | 2013-10-23 |
CN103364498B true CN103364498B (zh) | 2016-12-21 |
Family
ID=49366315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210404133.6A Active CN103364498B (zh) | 2012-04-10 | 2012-12-24 | 生物样本中美他卡韦及其代谢产物浓度的检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103364498B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1493301A (zh) * | 2002-10-29 | 2004-05-05 | 刘晓宇 | 6-甲氧基双脱氧鸟苷在制备抗乙肝药物中的应用 |
CN102070691A (zh) * | 2010-12-22 | 2011-05-25 | 南京长澳医药科技有限公司 | 一种美他卡韦晶型,其制备方法以及包含它的药物组合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110150836A1 (en) * | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
-
2012
- 2012-12-24 CN CN201210404133.6A patent/CN103364498B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1493301A (zh) * | 2002-10-29 | 2004-05-05 | 刘晓宇 | 6-甲氧基双脱氧鸟苷在制备抗乙肝药物中的应用 |
CN102070691A (zh) * | 2010-12-22 | 2011-05-25 | 南京长澳医药科技有限公司 | 一种美他卡韦晶型,其制备方法以及包含它的药物组合物 |
Non-Patent Citations (2)
Title |
---|
A sensitive and specific liquid chromatography–mass spectrometry method for determination of metacavir in rat plasma;Zhan Li etal.;《Journal of Chromatography B》;20081231;第864卷;第9-14页 * |
Simultaneous determination of metacavir and its metabolites in rat plasma using high‐performance liquid chromatography with tandem mass spectrometric detection (LC-MS/MS);Yue Zhang etal.;《Biomedical Chromatography》;20120331;第26卷(第3期);第364页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103364498A (zh) | 2013-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Guichard et al. | Antineoplastic drugs and their analysis: a state of the art review | |
Yang et al. | Determination of nucleosides and nucleobases in different species of Cordyceps by capillary electrophoresis–mass spectrometry | |
CN111562322B (zh) | 一种血样中五种抗肿瘤药物的富集检测方法及应用 | |
CN104991019B (zh) | 生物检材中钩吻素甲和钩吻素子的液相色谱-串联质谱检测方法 | |
CN108828077B (zh) | 一种同时检测血浆中卡培他滨及其代谢产物的试剂盒及其检测方法与应用 | |
CN105136957A (zh) | 一种同时测定人血浆中oxc以及代谢产物mhd和mhd-g的检测方法 | |
Yuan et al. | Rapid classification and identification of complex chemical compositions in traditional Chinese medicine based on UPLC-Q-TOF/MS coupled with data processing techniques using the KuDieZi injection as an example | |
Ding et al. | Determination of 6-mercaptopurine and azathioprine in plasma by high-performance liquid chromatography | |
CN102735764A (zh) | 一种血浆中利巴韦林含量的测定方法 | |
CN104558090A (zh) | 醋酸阿比特龙杂质及其测定方法 | |
CN106970176B (zh) | 一种测定肝微粒体中芍药苷代谢产物的方法 | |
CN104958330A (zh) | 一种木蝴蝶总黄酮的提取纯化方法及其应用 | |
Aboras et al. | A review on analytical strategies for the assessment of recently approved direct acting antiviral drugs | |
Oflu et al. | Combination of quadrupole isotope dilution mass spectrometry with simultaneous derivatization and spray assisted droplet formation-liquid phase microextraction for the determination of methamphetamine in human urine and serum samples by gas chromatography mass spectrometry | |
CN103364498B (zh) | 生物样本中美他卡韦及其代谢产物浓度的检测方法 | |
CN102818867B (zh) | 一种鉴别注射用核糖核酸ⅱ的方法 | |
Sparidans et al. | Improved and simplified liquid chromatographic assay for adefovir, a novel antiviral drug, in human plasma using derivatization with chloroacetaldehyde | |
Kim et al. | Determination of phloroglucinol in human plasma by high-performance liquid chromatography–mass spectrometry | |
CN103575814A (zh) | 血浆中5种黄酮和4种生物碱的检测方法 | |
CN104914193B (zh) | 生物样品中夹竹桃苷和夹竹桃苷乙的液相色谱-串联质谱检验方法 | |
Huo et al. | Simultaneous and sensitive determination of eight coumarins in rat bile and urine after oral administration of Radix Angelicae dahuricae extract by liquid chromatography-electrospray ionization-mass spectrometry | |
CN105334273A (zh) | 地枫皮的质量控制方法 | |
CN104569215B (zh) | 一种测定血浆中香紫苏醇浓度的方法 | |
Lin et al. | Simultaneous Determination of Doxofylline and its Metabolite Theophylline in Rat Plasma by Ultra Performance Liquid Chromatography | |
Li et al. | Simultaneous determination of multiple active components from bushen pills and application in a pharmacokinetic study in rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Xie Shaofei Inventor after: Yu Chengxia Inventor after: Zhou Dongyan Inventor after: Huang Haiyan Inventor after: Li Wei Inventor after: Wang Liquan Inventor before: Xie Shaofei Inventor before: Yu Chengxia Inventor before: Zhou Dongyan Inventor before: Huang Haiyan Inventor before: Li Wei |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: XIE SHAOFEI YU CHENGXIA ZHOU DONGYAN HUANG HAIYAN LI WEI TO: XIE SHAOFEI YU CHENGXIA ZHOU DONGYAN HUANG HAIYAN LI WEI WANG LIQUAN |
|
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU VANKING PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHANG'AO SCIENCE AND TECHNOLOGY OF MEDICAL INDUSTRY CO LTD, NANJING Effective date: 20141014 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210038 NANJING, JIANGSU PROVINCE TO: 510760 GUANGZHOU, GUANGDONG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20141014 Address after: 510760 Guangdong city of Guangzhou province Guangzhou economic and Technological Development Zone East Road No. 6 self building Applicant after: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. Address before: 210038 Nanjing economic and Technological Development Zone, Jiangsu Province, No. Wing Road, No. 1 Applicant before: NANJING CHANGAO PHARMACEUTICAL SCIENCE & TECHNOLOGY Co.,Ltd. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Hanxiong Inventor after: Xie Shaofei Inventor after: Yu Chengxia Inventor after: Zhou Dongyan Inventor after: Huang Haiyan Inventor after: Li Wei Inventor after: Wang Liquan Inventor before: Xie Shaofei Inventor before: Yu Chengxia Inventor before: Zhou Dongyan Inventor before: Huang Haiyan Inventor before: Li Wei Inventor before: Wang Liquan |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221116 Address after: No.6 Dongbo Road, East District, Guangzhou Economic and Technological Development Zone, Guangdong 510000 Patentee after: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. Patentee after: GUANGDONG ZERUI PHARMACEUTICAL Co.,Ltd. Patentee after: Guangzhou Lianrui Pharmaceutical Co.,Ltd. Patentee after: Guangzhou Runlin Pharmaceutical Technology Co.,Ltd. Patentee after: Euphorbia Biological Medicine Co.,Ltd. Address before: 510760 Building 1, No.6 Dongbo Road, Guangzhou Economic and Technological Development Zone, Guangzhou City, Guangdong Province Patentee before: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. |